CLL Society
WHAT’S NEW
Your connection to the most current news, information, and data about Chronic Lymphocytic Leukemia.
We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
COVID-19 Updates
FDA Pauses Authorization for Last Remaining COVID-19 Monoclonal Antibody Treatment
Bebtelovimab joins the long list of “here and gone” anti- SARS-CoV-2 monoclonal antibodies that are no longer reliably effective in treating COVID-19 due to mutations in the dominant variants of concern. For the past monoclonals such as REGEN-COV or sortovimab, Omicron rendered them ineffective.
CLL Society’s COVID-19 Update for the Week of November 28th, 2022
Here is your weekly summary of what has been happening this past week in the United States. The variant picture continues to shift rapidly. Read more on this below.
CLL Society’s COVID-19 Update for the Week of November 21st, 2022
Here is your weekly summary of what has been happening this past week in the United States. The variant picture continues to shift rapidly. Read more on this below.
Living with CLL
Are We Speaking the Same Language? Insights from a Patient and Provider Survey on CLL (Chronic Lymphocytic Leukemia)
Over the last few years, CLL Society has enjoyed working on several projects with the Association of Community Cancer Centers (ACCC) related to better understanding and improving the quality of care for CLL (chronic lymphocytic leukemia) patients in the community.
Support Group? Nah, Not for Me
I had always thought that a cancer support group was probably useful for some, but definitely not for me. Since my diagnoses of CLL/SLL about 11 years ago, my sole interest has been in getting information, current trends in treatment, potential new drugs, clinical trials, and trial results.
SPECIAL FEATURE: Giving Tuesday is Coming Next Week, November 29th
Being diagnosed with the cancer chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and finding out it is incurable can feel like it will be unbearable. For Lynn, getting connected to the community of patients and caregivers with CLL Society made what felt unbearable, bearable. Finding people who are learning to navigate the same decisions you are making is not only comforting, but it can be lifesaving as you learn what treatments may be right for you.
There are an estimated 200,000 people in the US living with CLL who are looking for answers sometimes only a fellow patient can provide.
This Giving Tuesday, CLL Society has set a goal of raising $50,000 to provide those touched by a diagnosis of CLL/SLL with the support and education they need to get their best care. You can help those impacted by CLL find their community when you join us on November 29th and make a donation.
Thanks to the generosity of an anonymous donor, all donations for
Giving Tuesday will be matched up to $25,000! Visit the campaign page to listen to Lynn’s full story and make your gift today.
ADVOCACY
CLL Society Included in Pinpoint Patient Recruiting Giving Tuesday Giveaway
Giving Tuesday is coming up on November 29th. This year, Pinpoint Patient Recruiting is conducting a Giving Tuesday Giveaway on social media and has included CLL Society as one of the organizations they believe is making a difference in the lives of patients with CLL/SLL!
You can vote for CLL Society by liking, sharing, and commenting on posts from Pinpoint about CLL Society and help us win up to $3,000 towards our Giving Tuesday campaign to support all those living with CLL/SLL. Spread the word with family and friends and make sure your vote is in by Monday, November 28th at midnight.
CLL Society Sends a Comment Letter to the Centers for Medicare and Medicaid Services (CMS)
CLL Society voiced strong support of the CMS proposal to continue the existing policy to pay for COVID-19 monoclonal antibodies and their administration (such as Evusheld) under the Part B vaccine benefit.
UPCOMING EVENTS
Monday, December 5, 2022 at 10 AM PT / 1 PM ET
Ask Me Anything Facebook Live Event
Join Dr. Nicole Lamanna and CLL patient advocate Doreen Zetterlund for CLL Society’s next Facebook Live event. With no prepared presentations, this is a time dedicated to getting the questions you have answered.
On-Demand Replay
If you missed the November 16th CLL Society Ed Forum focused on CLL basics, watch & wait, and an overview of treatments from Huntsman Cancer Institute team and patient advocate Stephen Feldman, you can catch the replay of the 6th Annual Patient & Caregiver Ed Forum here!
Treatment Updates
Obinutuzumab/Acalabrutinib/Venetoclax Combo Misses the Mark for MRD in Advanced Chronic Lymphocytic Leukemia (CLL)
The combination of obinutuzumab (Gazyva), acalabrutinib (Calquence), and venetoclax (Venclexta) failed to meet the pre-specified rate of undetectable measurable or minimal residual disease (uMRD) following optimal debulking with bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
ASH 2021: Increased Risk for Serious Infections Linked with Monoclonal B-Cell Lymphocytosis
Patients with monoclonal B-cell lymphocytosis (MBL), a precursor to chronic lymphocytic leukemia (CLL), were at increased risk of severe infections, according to an analysis of records from participants collected in the Mayo Clinic Biobank.
ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML
Very complex, promising research is currently underway to use humanized bispecific single-domain antibodies (bsVHH). But, unfortunately, harnessing the immune system can get very complicated. This article introduces an experimental antibody with a novel approach to fighting CLL/SLL.
Equitable Access and Regulatory News
ASCO 2022: Survival Outcomes in Patients with Chronic Lymphocytic Leukemia Treated at Academic Centers
Chronic lymphocytic leukemia (CLL) patients treated at academic centers live lived longer than those treated at non-academic centers, but the data was confounded by significant demographic and socioeconomic variation between CLL patients treated at Academic Centers and Non-Academic Centers.
